tiprankstipranks
Trending News
More News >
Kaken Pharmaceutical Co Ltd (JP:4521)
:4521
Advertisement

Kaken Pharmaceutical Co (4521) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Kaken Pharmaceutical Co

(OTC:4521)

Rating:72Outperform
Price Target:
¥4,241.00
▲(10.90%Upside)
Kaken Pharmaceutical Co has a strong financial foundation and attractive valuation, with significant revenue growth and profitability. However, technical analysis suggests cautious trading sentiment, with mixed signals and bearish momentum in the short term. The company's stable balance sheet and solid dividend yield support an overall positive outlook, despite the need for vigilance regarding market fluctuations.

Kaken Pharmaceutical Co (4521) vs. iShares MSCI Japan ETF (EWJ)

Kaken Pharmaceutical Co Business Overview & Revenue Model

Company DescriptionKaken Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company that operates within the healthcare sector. It is primarily engaged in the research, development, manufacture, and sale of pharmaceuticals and medical devices. The company's core products include prescription medications, dermatological treatments, and orthopedic devices. With a strong emphasis on innovation, Kaken Pharmaceutical focuses on providing solutions for unmet medical needs, particularly in areas like dermatology, orthopedics, and immunology.
How the Company Makes MoneyKaken Pharmaceutical Co., Ltd. generates revenue through the sale of its pharmaceutical products and medical devices. Its primary revenue streams include the sale of prescription drugs, particularly those used in dermatology and orthopedics. The company invests in research and development to create innovative therapies that address specific medical conditions, which in turn drives sales. Additionally, Kaken collaborates with other pharmaceutical companies and engages in licensing agreements to broaden its product portfolio and market reach. These partnerships and its strong distribution network contribute significantly to the company's earnings.

Kaken Pharmaceutical Co Financial Statement Overview

Summary
Kaken Pharmaceutical Co exhibits strong financial performance with robust profitability, solid revenue growth, and a stable balance sheet with low leverage. It demonstrates efficient cash management, though some historical volatility in revenue and cash flow suggests a need for cautious planning.
Income Statement
85
Very Positive
Kaken Pharmaceutical Co has demonstrated strong revenue growth, with a significant increase from the previous year, and robust profitability metrics. The Gross Profit Margin and Net Profit Margin improved significantly, standing at 61.96% and 14.83% respectively in the latest year. EBIT and EBITDA margins also showed solid performances at 22.37% and 23.42%. However, the revenue growth has been somewhat volatile in the past, indicating potential market fluctuations.
Balance Sheet
90
Very Positive
The company maintains a very healthy balance sheet with a low Debt-to-Equity Ratio of 0.025, which indicates low leverage and financial stability. Return on Equity is strong at 9.14%, reflecting efficient use of equity. The Equity Ratio stands at a healthy 80.16%, signifying a strong equity base. These metrics indicate a stable financial position with minimal financial risk.
Cash Flow
78
Positive
Kaken Pharmaceutical Co has seen substantial growth in Free Cash Flow, with a remarkable increase in the latest year. The Operating Cash Flow to Net Income Ratio is strong at 2.14, indicating good cash generation relative to net income. Despite these strengths, historical fluctuations in cash flow and a dip in Free Cash Flow in 2024 suggest potential volatility in cash generation.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue94.03B72.04B72.98B76.03B74.98B
Gross Profit58.26B38.54B39.56B41.58B40.91B
EBITDA22.02B12.57B10.57B16.38B20.11B
Net Income13.95B8.03B5.44B9.55B13.40B
Balance Sheet
Total Assets190.42B171.62B166.33B165.18B163.33B
Cash, Cash Equivalents and Short-Term Investments70.08B65.32B74.26B74.62B77.31B
Total Debt3.85B3.85B3.85B3.85B3.85B
Total Liabilities37.78B27.87B29.49B26.86B27.08B
Stockholders Equity152.63B143.75B136.26B137.75B136.26B
Cash Flow
Free Cash Flow25.64B410.00M7.05B10.08B12.09B
Operating Cash Flow29.78B2.58B9.25B13.34B14.38B
Investing Cash Flow-19.65B-5.85B-2.63B-7.89B-1.64B
Financing Cash Flow-5.37B-5.66B-6.99B-8.13B-8.75B

Kaken Pharmaceutical Co Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price3824.00
Price Trends
50DMA
3795.64
Positive
100DMA
4073.86
Negative
200DMA
4097.15
Negative
Market Momentum
MACD
-2.08
Negative
RSI
51.79
Neutral
STOCH
86.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4521, the sentiment is Neutral. The current price of 3824 is above the 20-day moving average (MA) of 3800.05, above the 50-day MA of 3795.64, and below the 200-day MA of 4097.15, indicating a neutral trend. The MACD of -2.08 indicates Negative momentum. The RSI at 51.79 is Neutral, neither overbought nor oversold. The STOCH value of 86.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4521.

Kaken Pharmaceutical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
¥157.24B8.2811.38%2.19%13.89%17.38%
72
Outperform
$137.74B10.469.44%3.01%30.52%73.96%
67
Neutral
¥101.07B18.524.35%2.69%5.31%90.37%
66
Neutral
$168.90B15.085.47%2.18%16.87%11.24%
65
Neutral
$177.54B31.984.56%1.90%9.56%5.09%
65
Neutral
¥192.80B20.08
2.51%-3.69%-18.73%
64
Neutral
¥342.82B11.02-2.99%2.56%11.77%-10.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4521
Kaken Pharmaceutical Co
3,824.00
-17.75
-0.46%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,939.50
-279.94
-12.61%
JP:4534
Mochida Pharmaceutical Co., Ltd.
2,970.00
-376.47
-11.25%
JP:4547
Kissei Pharmaceutical Co
4,135.00
927.99
28.94%
JP:4553
Towa Pharmaceutical Co
3,195.00
222.35
7.48%
JP:4551
Torii Pharmaceutical Co
6,320.00
2,674.99
73.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025